NCT01202721View on ClinicalTrials.gov

Beta Blockers and Angiotensin Receptor Blockers in Bicuspid Aortic Valve Disease Aortopathy (BAV Study)

PHASE3TerminatedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

April 19, 2016

Study Completion Date

November 30, 2016

Conditions
Cardiac Disease
Interventions
DRUG

Atenolol

Atenolol or matching placebo 25 mg up-titrated to 100 mg

DRUG

Telmisartan

Telmisartan or matching placebo 40 mg up-titrated to 80mg.

Trial Locations (13)

T6G 2B7

Mazankowski Alberta Heart Institute, Edmonton

V6Z 1Y6

University of British Columbia, Vancouver

Unknown

St. Boniface Hospital, Winnipeg

Toronto General Hospital/University of Toronto, Toronto

L8L 2X2

Hamilton Health Sciences-General, Hamilton

L8L2X2

Population Health Research Institute - Coordinating Centre, Hamilton

N6A 5A5

London Health Sciences Centre, London

M5B 1W8

St. Michael's Hospital, Toronto

H7M 3L9

Cité de la Santé de Laval, Laval

H3A 1A1

McGill University Health Centre, Montreal

H3T 1E2

Jewish General Hospital, Montreal

J1H 5N4

Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke

S4P 0W5

Regina General Hospital, Regina

Sponsors
All Listed Sponsors
collaborator

Population Health Research Institute

OTHER

lead

Hamilton Health Sciences Corporation

OTHER